TM6SF2 and hepatocellular carcinoma: Most of the data pointed at the role of TM6SF2 E167K variation in predisposing to all the NAFLD spectrum [26,28,29], although its impact on clinically relevant fibrosis and HCC is still controversial [29,30,31].